ACELRX PHARMACEUT. DL-01 Cash Flow-to-Debt Ratio
ACELRX PHARMACEUT. DL-01 cash flow-to-debt ratio. ACELRX PHARMACEUT. DL-01 (R5XA) has a Cash Flow-to-Debt Ratio of -0.19x as of December 2025, meaning its operating cash flow of €-2.44 Million could theoretically repay 0% of its total liabilities (€12.68 Million) in one year. Check R5XA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ACELRX PHARMACEUT. DL-01 (2021–2025)
Cash flow-to-debt ratio of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. Historical debt coverage capacity for ACELRX PHARMACEUT. DL-01 across 5 annual periods. Also explore R5XA net asset momentum to track the company's year-over-year net asset growth rate.
ACELRX PHARMACEUT. DL-01 Cash Flow-to-Debt Ratio by Year (2021–2025)
ACELRX PHARMACEUT. DL-01 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for ACELRX PHARMACEUT. DL-01. For the full cash flow conversion analysis, see cash efficiency ratio of ACELRX PHARMACEUT. DL-01.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.90x | €-11.36 Million | €12.68 Million | ▲ +27.7% |
| 2024 | -1.24x | €-12.68 Million | €10.23 Million | ▲ +55.4% |
| 2023 | -2.78x | €-17.49 Million | €6.29 Million | ▼ -152.0% |
| 2022 | -1.10x | €-28.33 Million | €25.67 Million | ▼ -318.5% |
| 2021 | -0.26x | €-30.00 Million | €113.79 Million | — |